Pier Capital’s Denali Therapeutics DNLI Stock Holding History

Pier Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-301,171	Closed	-$4.37M	–	137
2025 Q3	$4.37M	Sell	301,171 -13,625	-4%	-$196K	0.68%	74
2025 Q2	$4.4M	Sell	314,796 -20,708	-6%	-$291K	0.67%	73
2025 Q1	$4.56M	Buy	335,504 +3,185	+1%	+$61K	0.76%	65
2024 Q4	$6.77M	Buy	332,319 +164,237	+98%	+$4.2M	0.97%	66
2024 Q3	$4.9M	Buy	168,082 +2,596	+2%	+$64.3K	0.69%	81
2024 Q2	$3.84M	Sell	165,486 -6,845	-4%	-$131K	0.57%	86
2024 Q1	$3.54M	Sell	172,331 -1,888	-1%	-$35.5K	0.49%	89
2023 Q4	$3.74M	Buy	174,219 +49,139	+39%	+$973K	0.53%	87
2023 Q3	$2.58M	Sell	125,080 -2,048	-2%	-$51.9K	0.42%	91
2023 Q2	$3.75M	Buy	+127,128	New	+$3.57M	0.54%	89

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pier Capital's DNLI Position: Q4 2025 in Review

Pier Capital sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 301,171 shares — an estimated $4.37M sold.

Pier Capital first reported a position in DNLI in Q2 2023 and held it in 10 quarters. The position peaked at $6.77M in Q4 2024. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Pier Capital reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Pier Capital sold 301,171 Denali Therapeutics shares in Q4 2025, an estimated $4.37M.
Pier Capital first reported a position in Denali Therapeutics in Q2 2023 and held it in 10 quarters.
Pier Capital's Denali Therapeutics position peaked at $6.77M in Q4 2024.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Pier Capital's 13F filing for Q4 2025, filed 3 Feb 2026.